PRISM BioLab (206A) · TargetSoftened
Launch two proprietary programs each year
First written in FY2024. 1 of 3 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
Continuous creation of new drugs and pipeline expansionA theme 17 companies write about · 0 as a headwind · 23 as a tailwind
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Softened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 17 companies compared. The sentences above are computed from all 17.Full recordFilings, disclosures and news, newest first
- FY2025SoftenedAnnual report
「In addition to our proprietary programs currently under development, we aim to continuously create new programs by launching new programs each year, concentrating resources preferentially on programs with a high probability of success.」
The wording has changed from "2 each year" to "launching each year," with no number specified. During the fiscal year, 1 new proprietary program was launched. - FY2025-H1AdvancedAnnual report
「We have also decided to launch programs for 2 new drug targets and are preparing to do so.」
The decision has been made to launch programs for 2 new drug discovery targets, and preparations are underway. - FY2024First statedAnnual report
「We are continuing to evaluate drug targets for launching new programs and expect to launch 2 programs each year going forward.」
During the current fiscal year, we launched 1 new program and are advancing hit compound discovery.